The slowdown is largely attributed to a natural cooling after the rapid patient onboarding seen in April. With a significant portion of early adopters already initiated on therapy, repeat purchases are now emerging as the primary growth driver for the category.
The slowdown is largely attributed to a natural cooling after the rapid patient onboarding seen in April. With a significant portion of early adopters already initiated on therapy, repeat purchases are now emerging as the primary growth driver for the category.
<iframe src="https://hindustansphere.com/embed/cluster/dab85acf6520983fb250203d3a0255f4c69888cb" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Sun Pharma, Ozempic Defy Slowdown In India's Weight-Loss Market"></iframe>
